Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 20/20 | 1.00 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.64 |
| ▸ | BRD2 | P25440 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31392919 | 1.00 | BRD4 (1.00) | BRD4CREBBPBRD2 | |
| SCHEMBL20004257 | 0.78 | BRD4 (1.00) | BRD4CREBBPBRD2 | |
| SCHEMBL17581463 | 0.78 | BRD4 (0.64) | BRD4CREBBPBRD2 | |
| SCHEMBL859173 | 0.77 | BRD4 (0.64) | BRD4CREBBP | |
| SCHEMBL29422776 | 0.77 | BRD4 (0.64) | BRD4CREBBP | |
| SCHEMBL31735700 | 0.77 | BRD4 (1.00) | BRD4CREBBPBRD2 | |
| SCHEMBL18124120 | 0.77 | BRD4 (1.00) | BRD4CREBBPBRD2 | |
| SCHEMBL17813519 | 0.75 | BRD4 (0.66) | BRD4CREBBPBRD2 | |
| SCHEMBL17813564 | 0.74 | BRD4 (0.66) | BRD4CREBBP | |
| SCHEMBL31735610 | 0.74 | BRD4 (1.00) | BRD4CREBBPBRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12116365-B2 | Heterocyclic compounds and uses thereof | Opna Bio SA (CH) | 2024-10-15 | — | — | US | disclosed |
| US-20220356183-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Opna Bio SA (CH) | 2022-11-10 | — | — | US | disclosed |
| EP-4071149-A2 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Opna Immuno Oncology, SA (CH) | 2022-10-12 | — | — | EP | disclosed |
| US-11446287-B2 | Compounds and methods for EP300 or CBP modulation and indications therefor | OPNA IMMUNO-ONCOLOGY SA (CH) | 2022-09-20 | — | — | US | disclosed |
| EP-3953351-A1 | CONDENSED AZINES FOR EP300 OR CBP MODULATION AND INDICATIONS THEREFOR | Plexxikon Inc. (US) | 2022-02-16 | — | — | EP | disclosed |
| EP-3353179-B1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PLEXXIKON INC (US) | 2022-02-09 | — | — | EP | disclosed |
| CN-113710668-A | Condensed azines for EP300 or CBP modulation and indications therefor | 普莱希科公司 | 2021-11-26 | — | — | CN | disclosed |
| US-20210315872-A1 | COMPOUNDS AND METHODS FOR EP300 or CBP MODULATION AND INDICATIONS THEREFOR | Opna Bio SA (CH) | 2021-10-14 | — | — | US | disclosed |
| US-20210315872-A1 | COMPOUNDS AND METHODS FOR EP300 or CBP MODULATION AND INDICATIONS THEREFOR | Opna Bio SA (CH) | 2021-10-14 | — | — | US | disclosed |
| EP-3601281-B1 | CRYSTALLINE FORMS OF 4-(1-(1,1-DI(PYRIDIN-2-YL)ETHYL)-6-(3,5-DIMETHYLISOXAZOL-4-YL)-1H-
PYRROLO[3,2-B]PYRIDIN-3-YL)BENZOIC ACID THAT INHIBITS BROMODOMAIN | PLEXXIKON INC (US) | 2021-09-29 | — | — | EP | disclosed |
| EP-2970265-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PLEXXIKON INC. (US) | 2016-01-20 | — | — | EP | disclosed |
| US-20150133400-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Opna Bio SA (CH) | 2015-05-14 | — | — | US | disclosed |
| US-20150133400-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Opna Bio SA (CH) | 2015-05-14 | — | — | US | disclosed |
| US-20150133400-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Opna Bio SA (CH) | 2015-05-14 | — | — | US | disclosed |
| US-20140303121-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PLEXXIKON INC. | 2014-10-09 | — | — | US | disclosed |
| US-20140303121-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PLEXXIKON INC. | 2014-10-09 | — | — | US | disclosed |
| US-20140303121-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PLEXXIKON INC. | 2014-10-09 | — | — | US | disclosed |
| WO-2014145051-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | ZHANG JIAZHONG (US) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014145051-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | ZHANG JIAZHONG (US) | 2014-09-18 | — | — | WO | disclosed |
| US-8728631-B2 | Dendrimer compound and organic luminescent device employing the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2014-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12116365-B2 | Heterocyclic compounds and uses thereof | CYP11B2, CYP11B1, UGT2B7 | BRD4 1363/4885CREBBP 790/4885BRD2 2899/4885 |
| US-20140303121-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | CYP11B2, CYP11B1, CYP2C19 | BRD4 1365/4885CREBBP 1261/4885BRD2 2805/4885 |
| US-20150133400-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | CYP11B2, CYP11B1, CYP2C19 | BRD4 1365/4885CREBBP 1261/4885BRD2 2805/4885 |
| US-20220356183-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | CYP11B2, CYP11B1, UGT2B7 | BRD4 1363/4885CREBBP 790/4885BRD2 2899/4885 |
| US-11446287-B2 | Compounds and methods for EP300 or CBP modulation and indications therefor | EP300, CREBBP, HDAC11 | BRD4 6/4885CREBBP 2/4885BRD2 40/4885 |
| US-20210315872-A1 | COMPOUNDS AND METHODS FOR EP300 or CBP MODULATION AND INDICATIONS THEREFOR | EP300, CREBBP, HDAC11 | BRD4 6/4885CREBBP 2/4885BRD2 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.